Analyst Rating Update on Amicus Therapeutics (FOLD)

Amicus Therapeutics (NASDAQ:FOLD) : 7 analysts are covering Amicus Therapeutics (NASDAQ:FOLD) and their average rating on the stock is 1.29, which is read as a Strong Buy. 6 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Amicus Therapeutics (NASDAQ:FOLD) : The most positive equity analysts on Amicus Therapeutics (NASDAQ:FOLD) expects the shares to touch $19, whereas, the least positive believes that the stock will trade at $9 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $14 with an expected fluctuation of $3.83 from the mean.

For the current week, the company shares have a recommendation consensus of Buy. Also, Bank of America initiates coverage on Amicus Therapeutics (NASDAQ:FOLD). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Bank of America announces a current price target of $10 per share. The rating by the firm was issued on May 18, 2016.

Amicus Therapeutics (NASDAQ:FOLD): stock turned positive on Tuesday. Though the stock opened at $5.14, the bulls momentum made the stock top out at $5.49 level for the day. The stock recorded a low of $5.11 and closed the trading day at $5.43, in the green by 8.60%. The total traded volume for the day was 1,972,749. The stock had closed at $5 in the previous days trading.

In an insider trading activity, Rosenberg Ellen, officer (General Counsel & Corp. Secy) of Amicus Therapeutics Inc had purchased 15,000 shares on June 2, 2016 in a transaction. The price per share was $7.67 and the total amount of the disclosed transaction was $115,050.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *